TPST Tempest Therapeutics, Inc.
Price Chart
Executive Summary
Tempest Therapeutics' S-3 shelf registration (File No. 333-294740) became effective on April 3, 2026, allowing selling stockholders to immediately resell up to 2,777,781 shares of common stock. The company will not receive proceeds from these sales, but may receive up to $4 million if warrants are exercised. This follows recent clinical progress and a strategic acquisition, suggesting opportunistic capital flexibility rather than distress.
Actionable Insight
Monitor for insider or institutional selling activity in the near term, as the shelf effectiveness enables immediate resale. Any warrant exercises would be accretive to cash but dilutive to shares outstanding — track filings for exercise patterns. The neutral sentiment reflects lack of immediate company proceeds but ongoing capital market access.
Key Facts
- S-3 shelf registration (333-294740) became effective on April 3, 2026
- Registration covers resale of 2,777,781 shares by selling stockholders
- Shares include those issued in a recent private placement and upon warrant exercise
- Company will not receive proceeds from resale, but may receive up to $4 million from warrant exercises
- Follows strong clinical data and strategic acquisition, indicating proactive capital structure management
Financial Impact
Potential $4 million in future proceeds if all warrants are exercised; no immediate dilution from resale
Risk Factors
- Potential overhang from immediate resale of 2.8M shares by selling stockholders
- Future dilution if warrants are exercised, though proceeds would support operations
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001088 |
| Document: 9999999995-26-001088-index.html | 9999999995-26-001088 |
| Document: 9999999995-26-001088.txt | 9999999995-26-001088 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 29, 2026
11d ago
|
8-K
| $1.45 $1.27 | ▼ −12.41% | ▼ −9.66% | $1.27 (−12.41%) |
|
May 29, 2026
11d ago
|
Press Release
| $1.53 $1.27 | ▲ +16.99% | ▲ +16.70% | $1.27 (+16.99%) |
|
May 22, 2026
18d ago
|
8-K
| $1.77 $1.31 | ▲ +25.99% | ▲ +27.20% | $1.27 (+28.25%) |
|
May 22, 2026
18d ago
|
8-K
| $1.77 $1.31 | ▲ +25.99% | ▲ +27.20% | $1.27 (+28.25%) |
|
May 14, 2026
26d ago
|
8-K
| $1.83 $1.86 | ▼ −1.64% | ▼ −0.68% | $1.27 (+30.60%) |
|
Apr 29, 2026
5w ago
|
Press Release
| $1.74 $2.15 | ▲ +23.56% | ▲ +20.45% | $1.27 (−27.01%) |
|
Apr 6, 2026
9w ago
|
EFFECT
| $1.59 $2.14 | ▲ +34.59% | ▲ +30.46% | $1.27 (−20.13%) |
|
Apr 2, 2026
9w ago
|
S-3
| $1.59 $2.05 | ▲ +28.93% | ▲ +25.31% | $1.27 (−20.13%) |
|
Mar 30, 2026
10w ago
|
Press Release
| $1.52 $1.56 | ▲ +2.63% | ▼ −1.67% | $1.27 (−16.45%) |
|
Mar 11, 2026
12w ago
|
Press Release
| $2.40 $2.16 | ▼ −10.00% | ▼ −7.81% | $1.27 (−47.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access